Contraception and gynecological pathologies

Similar documents
Ardhanu Kusumanto Oktober Contraception methods for gyne cancer survivors

UKMEC SUMMARY TABLE HORMONAL AND INTRAUTERINE CONTRACEPTION

Contraception for Adolescents: What s New?

What s New in Adolescent Contraception?

Contraception Choices: An Evidence Based Approach Case Study Approach. Susan Hellier PhD, DNP, FNP-BC, CNE

Medical Eligibility for Contraception Use

Linda Gregg NP, Janet Isabell NP, Sue Montei NP Clinical Reviewers Reproductive Health Unit

2

Instruction for the patient

World Health Organization Medical Eligibility for Contraceptive Use. Connie Kraus, PharmD, BCACP Professor (CHS) Director Office of Global Health

HIV and contraception the latest recommendations

Management of Emergency Contraception (EC)

International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:

Contraceptive Updates and Recommendations

Contraceptive Updates and Recommendations

Contraception: Common Problems Faced in Office Practice. Jane S. Sillman, MD Brigham and Women s Hospital

Contraception update. Gina M. Brown, M.D.

Contraception update. Gina M. Brown, M.D.

The following lesson on contraception (birth control) is not intended to infer that you will be sexually active as a teen. This is information that

Wendy Shen, MD, PhD Refresher Course for the Family Physician April 5, 2018 Coralville, Iowa

Expanding Access to Birth Control: Will Women Get the Care They Need?

PERSONAL CHARACTERISTICS AND REPRODUCTIVE HISTORY...3 Pregnancy...3 Age...3 Parity...3 Breastfeeding...3 Postpartum...3 Post-abortion...

Disclosures. Objectives. Case: Anna. Case: Carla. Case: Beth. Contraception (for the Family Physician) 5/22/2015. Valary Gass, MD.

Application for inclusion of levonorgestrel - releasing IUD for contraception in the WHO Model List of Essential Medicines

Time Topic Speaker Abbreviation

Welcome to Mirena. The Mirena Handbook: A Personal Guide to Your New Mirena. mirena.com. Mirena is the #1 prescribed IUD * in the U.S.

The Balanced Counseling Strategy Plus: A Toolkit for Family Planning Service Providers Working in High STI/HIV Prevalence Settings.

2

Contraception. Objectives. Unintended Pregnancy. Unintended Pregnancy in the US. What s the Impact? 10/7/2014

An Overview of Long Acting Reversible Contraception Methods

U.S. Medical Eligibility Criteria for Contraceptive Use, 2010

CURRENT HORMONAL CONTRACEPTION - LIMITATIONS

FDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system)

Annex 2: GRADE evidence profiles

Unintended Pregnancy is Common LEARNING OBJECTIVES. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy And Contraceptive Use

Birth Control Options Chart

LEARNING OBJECTIVES. Beyond the Pill: Long Acting Contraception. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy is Common

The Doctor Is In. Brent N Davidson MD Vice Chair Women s Health Henry Ford Health System Medical Director Family Planning MDCH

the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD your guide to

Topics. Periods Menopause & HRT Contraception Vulva problems

1. Ng M et a l. Global, regional, and national prevalence of overweight and obesity in children and adults during : A systematic analysis

Question Bank III - BHMS

LARC: Disclosures. Long Acting Reversible Contraception. Objectives 10/23/2013. I have no relevant financial disclosures

Levosert levonorgestrel 20mcg/24hour intrauterine device

Contraception for Women and Couples with HIV. Knowledge Test

Questionnaire for Women

for Women Living with HIV Infection

HRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College

Dr Mary Birdsall. Fertility Associates Auckland

LONG-ACTING REVERSIBLE CONTRACEPTION. Summary Tables

Family Planning UNMET NEED. The Nurse Mildred Radio Talk Shows

Extended use of intrauterine devices: How long can we go?

DIP.G.O. EXAMINATION 2007

2/4/2011. What is your specialty? A. Family practice B. Internal medicine and subs C. OB/GYN D. Peds E. Surgery and subs

New Patient Medical History

Frequency of menses. Duration of menses 3 days to 7 days. Flow/amount of menses Average blood loss with menstruation is 60-80cc.

Palm Beach Obstetrics & Gynecology, PA

Chapter 100 Gynecologic Disorders

Abnormal Uterine Bleeding Case Studies

Long Acting Reversible Contraception: First Line Care for Adolescents. David A. Levine, MD, FAAP Melissa Kottke, MD, MPH, FACOG

Contraceptives. Kim Dawson October 2010

Hormonal Contraception: Asian View. Hormonal Contraception: Asian View: focused on Chinese View. Prof.Dr.Xiangyan Ruan, MD.PhD

Fertility control: what do women want?

2. Studies of Cancer in Humans

Hormonal Contraception and HIV: The WHO Responds. Ward Cates MTN Annual Meeting February 21, 2012

Instructions how to use the ESC teach the teachers course and self-learning tool

Birth Control -- Especially for Teens

Product Information. Confidence that lasts

Family Planning د. نجمه محمود كلية الطب جامعة بغداد فرع النسائية والتوليد

University Gynecologic Oncology Associates

1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S.

Contraception for young people. Dr Cindy Farmer Bristol Sexual Health Services Fri 8 th May 2015

Contraception Update: what s new in 2016? Felicity Young MA BSc (Hons) RMN RGN RM NDFSRH A08 Consultant Nurse for Sexual and Reproductive Healthcare

CONTRACEPTION IN HIV INFECTION DR JYOTI DHAR LEICESTER UK

Disclosures CONTRACEPTION COUNSELING IN MEDICALLY COMPLEX ADOLESCENTS. Aletha Akers, MD, MPH and Lyndsey Benson, MD, MS

Emergency Contraception THE FACTS

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories

Please fill out the following information and have it returned to our office prior to your consultation.

CLEAR COVERAGE HYSTERECTOMY CHECKLISTS

Removing Unnecessary Barriers to Contraceptive Services

Simplifying Vide Contraception. University of Utah Department of Ob/Gyn Post Grad Course February 13, 2017 David Turok

CONTRACEPTION OLD FRIENDS, NEW TRENDS

Table I. Examples of Hormone and Tapering Regimens

Reproductive Health Care: Agenda. Reproductive Health Care: Reproductive Life Plans. Reproductive Life Plans: Provider Prospective

Dr. Nancy Van Eyk Associate Professor, Dalhousie University Chief of Gynaecology, IWK Health Centre

Instructions how to use the ESC teach the teachers course and self-learning tool

Breast Cancer Risk in Patients Using Hormonal Contraception

Hormonal contraception and HIV risk

Primary Care Gynaecology Guidelines: HEAVY REGULAR MENSTRUAL BLEEDING

Contraceptive case studies. Dr Christine Roke National Medical Advisor Family Planning June 2015

Menstrual Disorders & Ambulatory Gynaecology

Disclosures. Learning Objectives 4/18/2017 ADOLESCENT CONTRACEPTION UPDATE APRIL 28, Nexplanon trainer for Merck

Chapter 7 Infertility, Contraception, and Abortion

Jean Anderson, MD Catherine Sewell, MD, MPH

BLEEDING PATTERNS AND CONTRACEPTIVE DISCONTINUATION FG MHLANGA MTN ANNUAL MEETING 20 MARCH 2018

Austin Fertility and Reproductive Medicine

levonorgestrel 13.5mg intrauterine delivery system (Jaydess ) SMC No. (1036/15) Bayer

Contraception Effective Methods of Birth Control

Medical treatment for uterine fibroids

Family Planning and Infertility

Transcription:

1 Contraception and gynecological pathologies

18 years old, 2 CMI normal First menstruation at 14 years old Irregular (every 2/3 months), painful + She does not need contraception She is worried about the irregularity of her cycle but says that the pain is tolerable.

3 Teen agers and troubles of the menstrual cycle No need to give COC only for irregular cycle Need to explain that irregular cycles are normal and that she is fertile No need of hormonal blood test Dysmenorrhea can be treated by NSAID If Dysmenorrhea not controlled by NSAID, hormonal contraception can be an alternative

4 20 years old Nulliparous No family or personnal history of CVD Complaining of her hypertrichosis Needs a contraception

Hypertrichosis and hormonal contraception 5 L hypertrichosis is not androgenic dependent and is only an excess of hair growth Hirsutism : excess hair on a male distribution pattern, such as facial and chest areas. Hormonal screening usually normal

Hypertrichosis and 6 contraception CHCs don t make it worse Some COC containing Cyprotèrone acetate(diane 35 ) are doing well decreasing hair When tolerance to this hypertrichosis is bad Acetate de cyproterone (Androcur 50 mg ) will improve significantly (add estrogene ).

Uterine fibroids 7 Mrs A, 42 years old, nulliparous has a large uterus and US noted: Fibroid uterus 11*10 Menstruations regular/5 days and heavy (always she said) No smoking No personal or family history of CVD Which contraception could be prescribed?

Myomas/endometriosis 8 Myomas - All contraception is possible depending of the localization and of the size of the myoma - Progestogen are not efficient to decrease myomas - IUD possible if no distorsion of the cavity

Endometriosis 9 Adenomyosis, endometriosis - COC or progestin-only pill recommended (continuous treatment) - Hormonal IUD if heavy bleeding Endometriosis ovarian cyst COC is not a treatment No contraindication

Ovarian cyst 10 Functional ovarian cyst COC is not a treatment for functional cysts COC prevents functional cysts Some COC (triphasic one) or progestin-only pill can generate functional cysts History of ovarian benign tumor or border line tumor Hormonal contraception is not contraindicated

11 Contraception after cervical therapy procedure (conization) Mrs B. 32 years old had a conization 2 years ago for CIN III. - Normal Pap test since conization - Has two children and wants another one in one or two years She is concerned about his fertility but wants a contraception. Which contraception could be advised?

12 Contraception after cervical therapy procedure (conization) After cervical therapy procedure, fertility rate does not decrease Cervical disease is not hormono-dependant but a viral and a STD - All contraception are possible - IUD possible Expulsion rate of IUD not more frequent

13 Contraception and benign breast disease You have prescribed COC to Mrs D. 38 years old She comes back 6 months later because she feels something in her breast. Mammogram and US (and biopsy) conclude adenofibroma of 3 cm. Do you switch for an other contraception?

14 Contraception and benign breast disease Benign breast pathology is not a risk factor of breast cancer Adenofibromas are benign and will not become a cancer Hormonal contraception is not contraindicated Decrease sometime with COC Brest cysts No contraindication for hormonal contraception

Family history of breast cancer 15 Mrs D. is 30 years old. Her mother had a breast cancer when she was 55yo Her aunt when she was 60 yo. She wants pills and nothing else. Will you prescribe? Which one?

Family history of breast cancer 16 WHI and the Million Study don t find an increase of risk of breast cancer when in the family history (first degree) cancer occurs after menopause ( Million study et WHI 2002) No excess risk of breast cancer with COC when there is a family history of breast cancer ( Breast cancer and hormonal contraception : 54 epidémiologicals studies Lancet 1996 347 ) Recommendation All contraception are possible (hormonal and non hormonal)

Contraception and breast 17 cancer 42 years old, breast cancer 3 years ago Under medical supervision, is fine. Condom use but has a new regular partner and ask for another contraception. Which contraception will you recommend?

Contraception and breast 18 cancer Contraindication of all hormonal contraception regardless the type of hormones or routes IUD progestin does not increase the risk of breast cancer but is is not recommended (no studies) Copper IUD : YES Barriers method//sterilization

19 Relationship between hormonal contraception and genital cancers

20 Relationship between hormonal contraception and cervical cancer 28 studies including 12 531 femmes COC users with a cervical cancer (compared to COC non users). Taking into account number of sexual partners, screening, smoking or use of condom, there is an increase risk with duration of COC use OR : 1.1 < 5 years OR : 1,6 >5 and < 9 years OR : 2.2 > 10 years The risk decreases when COC is stopped Lancet 2003: 361: 1159-1167 Smith JS

Relationship between hormonal contraception and ovarian cancer 21 Ovarian cancer is the second most common gynecologic malignancy and is associated with 5-year survival rates between 20% and 30%. 13 cohort studies et 32 case-control studies : 31% of the cancer cases were COP users versus 39% for non COC users To use COC 5 to 9 years reduces of 1/3 the risk of ovarian cancer and the effect lasts for at least 10 years After 15 years decrease of more t han half Collaborative group on epidémiological studies of ovarian cancer Lancet 2008 371: 303-314

Relationship between hormonal contraception and endometrial cancer 22 Risk of endometrial cancer is reduced by 20% after 1 year and by about 50% after 4 years of use Protective effect : 15 years

23 Relationship between hormonal contraception and breast cancer Research findings difficult to interpret 1. Meta analysis with 54 case controls studies (Kumle cancer epidemiology 2002) 53 297 breast cancers/100 239 controls In COC users : OR 1.24 ( IC à 95% 1.15-1.33) But these women have more screening No excess risk after discontinuation 10 years ago 2. Scandinavian prospective study 1992-1999 103 027 women/1008 breast cancers In COC and POP users OR : 1.6 ( IC à 95% 1.2-2.21)

24 Relationship between hormonal contraception and breast cancer 3. Case controls survey ; (NEJM PA.Marchbanks 2002) women 35-64 years old 4575 breast cancers/4682 controls COC users OR 1 ( IC to 95% 0.8-1.3) No excess risk whatever the duration of exposure, the dose of estrogen, the age at the beginning and the family history

Medical eligibility criteria for contraceptive use in case of gynecological pathologies 25 NO HORMONAL METHOD : breast cancer No restriction for hormonal method: Fibroids uterus, endometriosis History or cervical intra epithelial neoplasia (CIN) Family history of breast cancer Benign breast disease (fibroma, cyst) History of benign or border line ovarian tumor History of trophoblastic disease or during the follow up of hcg Thyroid disease WHO criteria eligibility 2009

26 Contraception for women infected with HIV or have AIDS

27 Contraception for women infected with HIV or have AIDS 1. Contraceptive methods and increase risk of HIV acquisition in women 1. Interaction between antiretroviral therapy (ARV) and hormonal contraceptive

Hormonal contraceptive methods and risk of HIV acquisition in women 28 Data do not support an association between use of oral contraceptives and increased risk of HIV acquisition Uncertainty persists regarding whether an association exists between depot-medroxyprogesterone acetate (DMPA) use and risk of HIV acquisition. No data have suggested significantly increased risk of HIV acquisition with use of implants, though data were limited. No data are available on the relationship between use of contraceptive patches, rings, or hormonal intrauterine devices and risk of HIV acquisition Polis CB, et al. Contraception. 2014 Oct;90(4):360-390.

Contraceptive methods and risk of HIV acquisition in women 29 Spermicids (nonoxynol): not recommended when used several time a day May even increase the risk of infection because it affects the vaginal lining in such a way that any HIV that was not killed could enter the system through vaginal tissue Polis CB, et al. Contraception. 2014 Oct;90(4):360-390.

Case study 30 Contraception and HIV 32 years old, HIV + for 10 years, 2 abortions Adequately controlled by the treatment Viral load negative Her partner is HIV negative

Contraception and HIV 31 If viral load negative, condom is not essential Recommendation (WHO, 2009) COCs,POP, POI, implants, can be used unless their therapy includes ritonavir which may reduce the effectiveness of hormonal contraception Emergency contraception (EC) - ARV therapy (favirenz (Sustiva ) or névirapine (Viramune ) may reduce the effectiveness of levonorgestrel (LNG). - Double the dose of LNG is an option but no data - No data on interaction with ulipristal

IUD and women with infected with HIV or have AIDS (WHO criteria eligibility 2009 32 IUDs can be used in case of HIV infection, except for women with AIDS and those not on antiretroviral therapy. No need to remove IUD if a woman develops AIDS while she had an IUD in place. IUD use by HIV-infected women has not been associated with increased risk of infection-related complications. The fact that copper-bearing IUDs may increase menstrual bleeding, and subsequently the risk of anemia, has to be taken into account in case of HIV positive women; Stringer EM, Kaseba C, Levy J, et coll. (2007) A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol 197 (2): 144.e1-8 Richardson BA, Morrison CS, Sekadde-Kigondu C, et coll. (1999) Effect of intrauterine device use on cervical shedding of HIV-1 DNA. AIDS 22; 13 (15): 2091-7

33 Interaction between antiretroviral therapy (ARV) and hormonal contraceptive ARV (ritonavir) reduce the effectiveness of hormonal contraception But also probably nelfinavir,, lopinavir (Kaletra) et névirapine (Viramune) Increase thromboembolic risk for efavirenz, indinavir, atanazavir et fozamprézavir? Be aware of drugs interaction when associated treatment (tuberculosis, epilepsy).

Contraception for women infected 34 with HIV or have aids Back up contraception with hormonal methods when they are on ARV therapy because reduce the effectiveness of hormonal contraception Urge women to use condoms along with all other contraceptive methods Only condom protect against IST and HIV.

35 Contraception and liver disease

36 34 years old, primiparous Cholestasis during the pregnancy Delivery 3 month ago She wants to take the COC she was used to

History of cholestasis pregnancy 37 related - Cholestasis disappears few days after the delivery. Recommendation (WHO criteria eligibility 2009) - Combined C. generally can be used but has to be stopped and not any more taken if jaundice appears - POC can be used in any circumstances

Liver disease (WHO, 2009) 38 Gall bladder disease Recommendation (WHO criteria eligibility 2009) Treated by cholecystectomy : Hormonal contraception can generally be used Medically treated : Combined contraception not to be used except if asymptomatic POP can generally be used

39 Liver disease (WHO, 2009)